News & Analysis as of

Antitrust Violations › Pharmaceutical Industry › Anticompetitive Behavior

Barnea Jaffa Lande & Co.

Increased Enforcement in Pharmaceutical Sector: BMS and Neopharm to Pay ILS Tens of Millions for Delaying Entry of Competing Drug

Barnea Jaffa Lande & Co. on

The Israel Competition Authority (ICA) recently published a draft consent decree signed with the international pharmaceutical company Bristol-Myers Squibb (BMS) and the Israeli pharmaceutical distributor Neopharm. Under the...more

Health Care Compliance Association (HCCA)

DOJ pursues antitrust violations in pharmaceutical industry

Health Care Compliance Association (HCCA) on

Compliance Today (November 2020) - An ongoing U.S. Department of Justice (DOJ) investigation into price-fixing, bid-rigging, and other antitrust behavior in the pharmaceutical industry has resulted in seven companies...more

Haug Partners LLP

INSIGHT: Abbvie Defeats Novel Antitrust Claims Against Humira Patent Estate—Lessons Learned

Haug Partners LLP on

A federal district court recently dismissed a lawsuit against AbbVie and biosimilar manufacturers of adalimumab involving a novel antitrust claim against the Humira patent estate. Attorneys with Haug Partners LLP take an...more

White & Case LLP

FTC and FDA Announce Plans to Combat Anticompetitive Practices in the "Biologic Marketplace"

White & Case LLP on

On February 3, 2020, the Federal Trade Commission ("FTC") and the Food and Drug Administration ("FDA") issued a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive...more

Akerman LLP - Health Law Rx

Pharmacies Accuse Drug Maker of Anticompetitive Contracting to Restrict Biosimilar Market

Akerman LLP - Health Law Rx on

Walgreens and Kroger have filed an antitrust action in the United States District Court for the Eastern District of Pennsylvania accusing Johnson & Johnson (J&J) of engaging in anticompetitive conduct designed to stymie the...more

Tarter Krinsky & Drogin LLP

Protecting Against Big Pharma's Tactics for Delaying Market Entry of Generics

Tarter Krinsky & Drogin LLP on

Branded companies make millions of dollars each day that a generic version of a drug is held from the market. Therefore, the branded companies are highly motivated to obstruct the path of generic pharma companies. For some...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide